COMPANY
BioVentrix
BioVentrix is a privately held medical device company headquartered in Mansfield, MA USA. From company website Source · Oct 12, 2026
Funding and NIH signals
- SEC Form D raise Raised $1.2M in debt securities (Form D filed Oct 8, 2026); +1 other Form D filing in the last 12 months. SEC Form D 0001283259-26-000005 (Oct 8, 2026)
Evidence (2 events)
- Oct 8, 2026 · SEC Form D 0001283259-26-000005
Name of Issuer: BIOVENTRIX, INC.; CIK: 1283259; Address: Mansfield, MA; Submission type: D; Filing date: 2026-10-08; Industry Group: Biotechnology; Date of First Sale: 2026-09-29; Types of Securities Offered: Debt, Option/warrant, Security to be acquired; Business combination transaction: false; Total Offering Amount: 3000000; Total Amount Sold: 1200000; Federal exemptions: 06b - Apr 24, 2026 · SEC Form D 0001283259-26-000002
Name of Issuer: BIOVENTRIX, INC.; CIK: 1283259; Address: Mansfield, MA; Submission type: D; Filing date: 2026-04-24; Industry Group: Other; Date of First Sale: 2026-04-16; Types of Securities Offered: Other (Secured Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 6000000; Total Amount Sold: 705000; Federal exemptions: 06b || Name of Issuer: BIOVENTRIX, INC.; CIK: 1283259; Address: Mansfield, MA; Submission type: D/A; Filing date: 2026-09-01; Industry Group: Other; Date of First Sale: 2026-04-16; Types of Securities Offered: Other (Secured Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 2765000; Federal exemptions: 06b || Name of Issuer: BIOVENTRIX, INC.; CIK: 1283259; Address: Mansfield, MA; Submission type: D/A; Filing date: 2026-09-09; Industry Group: Other; Date of First Sale: 2026-04-16; Types of Securities Offered: Other (Secured Convertible Promissory Notes); Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 2965000; Federal exemptions: 06b
- Oct 8, 2026 · SEC Form D 0001283259-26-000005
Timeline
- Trial start Not phased (device or behavioral study): RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial source ↗
- Trial start Not phased (device or behavioral study): Randomized Evaluation and Verification of Ventricular Enhancement source ↗
- Trial start Not phased (device or behavioral study): BioVentrix Revivent TC™ System Clinical Study source ↗
- Trial start Phase 1: Clinical Study of the BioVentrix Revivent TC for the Treatment of Ischemic Cardiomyopathy source ↗
- Trial start Not phased (device or behavioral study): Safety and Efficacy Study of the BioVentrix PliCath HF System source ↗
- Trial start Not phased (device or behavioral study): Prospective Study of the BioVentrix PliCath HF™ System for the Treatment of Ischemic Cardiomyopathy source ↗
- Trial start Not phased (device or behavioral study): Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity source ↗
Upcoming milestones
- 2028-08 (ESTIMATED) · Not phased · RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial · NCT06813820
Clinical trials (lead sponsor) 8
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06813820 | RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial | Not phased (device or behavioral study) | Recruiting | Sep 29, 2025 | 2028-08 (estimated) |
| NCT03845127 | Randomized Evaluation and Verification of Ventricular Enhancement | Not phased (device or behavioral study) | Withdrawn | Jan 1, 2020 | Dec 31, 2024 (actual) |
| NCT05710042 | ALIVE Expended Access - Clinical Study | Not listed | No longer available | Not listed | Not listed |
| NCT02931240 | BioVentrix Revivent TC™ System Clinical Study | Not phased (device or behavioral study) | Active, not recruiting | Aug 29, 2017 | Dec 31, 2023 (estimated) |
| NCT00326690 | Study Tests Whether a Standardized LVR Performed With the Blue Egg Device Improves Cardiopulmonary Exercise Capacity | Not phased (device or behavioral study) | Withdrawn | 2005-11 | 2008-12 (actual) |
| NCT02553785 | Clinical Study of the BioVentrix Revivent TC for the Treatment of Ischemic Cardiomyopathy | Phase 1 | Completed | 2015-06 | 2019-12 (actual) |
| NCT01568138 | Prospective Study of the BioVentrix PliCath HF™ System for the Treatment of Ischemic Cardiomyopathy | Not phased (device or behavioral study) | Completed | 2010-08 | 2015-08 (actual) |
| NCT01568164 | Safety and Efficacy Study of the BioVentrix PliCath HF System | Not phased (device or behavioral study) | Completed | 2012-03 | 2019-12 (actual) |
Raises and investors new
- Raise Private raise (SEC Form D): $1.2M sold of $3.0M offered; issuer “BIOVENTRIX, INC.”. Verified from the SEC filing. SEC filing ↗